Thus, we demonstrated that the TCRs expressed on empirically expanded CD8+ (Pt3) or CD4+ (Pt 38) opT cells were sufficient to confer tumor-recognition ability in a patient-specific manner. This evidence concerns the gene CD8A and neoplasm.